{'52WeekChange': 0.6071428,
 'SandP52WeekChange': None,
 'address1': '170 North Radnor Chester Road',
 'address2': 'Suite 250',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 1.75,
 'askSize': 4000,
 'averageDailyVolume10Day': 2021912,
 'averageVolume': 1415022,
 'averageVolume10days': 2021912,
 'beta': 2.265546,
 'beta3Year': None,
 'bid': 1.71,
 'bidSize': 4000,
 'bookValue': 0.497,
 'category': None,
 'circulatingSupply': None,
 'city': 'Radnor',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 1.79,
 'dayLow': 1.71,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -1.713,
 'enterpriseToRevenue': None,
 'enterpriseValue': 102976104,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 2.3917143,
 'fiftyTwoWeekHigh': 3.5,
 'fiftyTwoWeekLow': 1.01,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 72806339,
 'forwardEps': -0.57,
 'forwardPE': -3.017544,
 'fromCurrency': None,
 'fullTimeEmployees': 40,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.00625,
 'heldPercentInstitutions': 0.70287,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/marinuspharma.com',
 'longBusinessSummary': 'Marinus Pharmaceuticals, Inc., a clinical stage '
                        'pharmaceutical company, focuses on developing and '
                        'commercializing therapeutics to treat rare seizure '
                        'disorders. Its clinical stage product candidate, '
                        'ganaxolone, is an allosteric modulator of GABAA, '
                        'developed in formulations for two routes, including '
                        'intravenous (IV) and oral for adult and pediatric '
                        'patient populations in acute and chronic care, and '
                        'in-patient and self-administered settings. The '
                        "company's ganaxolone product candidate, acts at "
                        'synaptic and extrasynaptic GABAA receptors and '
                        'exhibits anti seizure, antidepressant, and anxiolytic '
                        'actions through its effects on. It is developing '
                        'ganaxolone for status epilepticus, cyclin dependent '
                        'kinase like 5 deficiency disorder, PCDH19-related '
                        'epilepsy, tuberous sclerosis complex, postpartum '
                        'depression, and treatment resistant depression. '
                        'Marinus Pharmaceuticals, Inc. has a collaboration '
                        'agreement with NovaMedica, LLC; and license and '
                        'supply agreements with Purdue Neuroscience Company '
                        'and CyDex Pharmaceuticals, Inc. The company was '
                        'founded in 2003 and is based in Radnor, Pennsylvania.',
 'longName': 'Marinus Pharmaceuticals, Inc.',
 'market': 'us_market',
 'marketCap': 210190880,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_7606380',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -69190000,
 'nextFiscalYearEnd': 1640908800,
 'open': 1.79,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -0.11,
 'phone': '484-801-4670',
 'previousClose': 1.8,
 'priceHint': 4,
 'priceToBook': 3.4607646,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 1.79,
 'regularMarketDayLow': 1.71,
 'regularMarketOpen': 1.79,
 'regularMarketPreviousClose': 1.8,
 'regularMarketPrice': 1.79,
 'regularMarketVolume': 1130703,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 122195000,
 'sharesPercentSharesOut': 0.0725,
 'sharesShort': 7622845,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 6657520,
 'shortName': 'Marinus Pharmaceuticals, Inc.',
 'shortPercentOfFloat': 0.0727,
 'shortRatio': 5.26,
 'startDate': None,
 'state': 'PA',
 'strikePrice': None,
 'symbol': 'MRNS',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.097,
 'twoHundredDayAverage': 2.2248561,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': 'fa2311e7-a277-341e-95c3-c3f56aa168dd',
 'volume': 1130703,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.marinuspharma.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '19087'}